



Results are displayed in a computed author sort order. The Publication Date timeline is not available.

- 1 [BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.](#)  
Finkle CD, St Pierre A, Leblond L, Deschenes I, DiMaio J, Winocour PD.  
Thromb Haemost. 1998 Feb;79(2):431-8.  
PMID: 9493603
- 2 [Effective use of BCH-2763, a new potent injectable direct thrombin inhibitor, in combination with tissue plasminogen activator \(tPA\) in a rat arterial thrombolysis model.](#)  
Deschênes I, Finkle CD, Winocour PD.  
Thromb Haemost. 1998 Jul;80(1):186-91.  
PMID: 9684808
- 3 [Insertion of the Asp-Ser/Phe sequence in the P' position of hirutonin provides molecules having both antithrombin and disintegrin activity.](#)  
Leblond L, DiMaio J, **Winocour PD**.  
Thromb Res. 1999 Feb 15;93(4):171-81. doi: 10.1016/s0049-3848(98)00182-0.  
PMID: 10064272
- 4 [In vitro and in vivo properties of bicyclic lactam inhibitors: a novel class of low molecular weight peptidomimetic thrombin inhibitors.](#)  
Leblond L, Groulx B, Boudreau C, Yang Q, Siddiqui MA, **Winocour PD**.  
Thromb Res. 2000 Nov 1;100(3):195-209. doi: 10.1016/s0049-3848(00)00333-9.  
PMID: 11108907
- 5 [Potent bicyclic lactam inhibitors of thrombin: Part I: P3 modifications.](#)  
St-Denis Y, Augelli-Szafran CE, Bachand B, Berryman KA, DiMaio J, Doherty AM, Edmunds JJ, Leblond L, Lévesque S, Narasimhan LS, Penvose-Yi JR, Rubin JR, Tarazi M, Winocour PD, Siddiqui MA.  
Bioorg Med Chem Lett. 1998 Nov 17;8(22):3193-8. doi: 10.1016/s0960-894x(98)00550-2.  
PMID: 9873701
- 6 [Antithrombotic effects of BCH 2763, a new direct thrombin inhibitor, in a canine model of venous thrombosis.](#)  
McClanahan TB, Ignasiak DP, Juneau P, Finkle C, **Winocour PD**, Gallagher KP.  
J Thromb Thrombolysis. 1999 Jun;7(3):301-6. doi: 10.1023/a:1008987211850.  
PMID: 10375391
- 7 [Potent and selective bicyclic lactam inhibitors of thrombin. Part 4: transition state inhibitors.](#)  
Bachand B, Tarazi M, St-Denis Y, Edmunds JJ, **Winocour PD**, Leblond L, Siddiqui MA.  
Bioorg Med Chem Lett. 2001 Feb 12;11(3):287-90. doi: 10.1016/s0960-894x(00)00636-3.  
PMID: 11212093
- 8 [Novel bicyclic lactam inhibitors of thrombin: highly potent and selective inhibitors.](#)  
St-Denis Y, Lévesque S, Bachand B, Edmunds JJ, Leblond L, Préville P, Tarazi M, **Winocour PD**, Siddiqui MA.  
Bioorg Med Chem Lett. 2002 Apr 22;12(8):1181-4. doi: 10.1016/s0960-894x(02)00131-2.  
PMID: 11934583
- 9 [Novel bicyclic lactam inhibitors of thrombin: potency and selectivity optimization through P1 residues.](#)  
Lévesque S, St-Denis Y, Bachand B, Préville P, Leblond L, **Winocour PD**, Edmunds JJ, Rubin JR, Siddiqui MA.  
Bioorg Med Chem Lett. 2001 Dec 17;11(24):3161-4. doi: 10.1016/s0960-894x(01)00661-8.

10 [Incorporation of an Asp-Ser sequence to form an RGDS-like motif in hirutonin: the effect on in vitro platelet function.](#)  
van Wyk V, Leblond L, **Winocour PD**, Devine DV, Gyongyossy-Issa MI.  
Thromb Res. 2000 Aug 15;99(4):343-52. doi: 10.1016/s0049-3848(00)00257-7.  
PMID: 10963785

FOLLOW NCBI



Connect with NLM



National Library of Medicine  
8600 Rockville Pike  
Bethesda, MD 20894

Web Policies  
FOIA  
HHS Vulnerability Disclosure  
Help  
Accessibility  
Careers

NLM | NIH | HHS | USA.gov